



Performance Note
HB0475 - Genetic Testing
Coverage Amendments
Sponsor: Rep. Ward, Raymond P.



Performance Note Report

Author: Kim Beck

Agency: Department of Health

Funding For:

New Services or Benefit

Public Benefit:

Purpose: To cover in-vitro fertilization and genetic testing for qualified enrollees as defined in lines 34-39, diagnosed with cystic fibrosis, spinal muscular atrophy, or Morquio Syndrome.

Services: In-vitro fertilization and genetic testing for qualified enrollees with a diagnosis of cystic fibrosis, spinal muscular atrophy, or Morquio Syndrome and the embryo that results from an in vitro-fertilization.

Expected Outcome: Coverage for in vitro fertilization resulting in children for qualified enrollees who may not otherwise have children and the ability to diagnosis an embryo that results from an in-vitro fertilization with cystic fibrosis, spinal muscular atrophy, or Morquio Syndrome.

Implementations and Resources: The department will need to apply for a waiver from the Centers for Medicare and Medicaid Services (CMS), if the waiver is approved the department will provide coverage of the services outlined for in-vitro fertilization and genetic testing for qualified enrollees diagnosed with cystic fibrosis, spinal muscular atrophy, or Morquio Syndrome and the genetic testing of the embryo that results from in-vitro fertilization.

How: If the waiver is approved by CMS the department will provide coverage for in-vitro fertilization and genetic testing for qualified enrollees that have been diagnosed with with cystic fibrosis, spinal muscular atrophy, or Morquio Syndrome and the genetic testing of the embryo that results from in-vitro fertilization.

Performance Measures

Goal

Title: Coverage for in-vitro fertilization and genetic testing.

Description: Provide coverage for in-vitro fertilization and genetic testing for qualified enrollees that have been diagnosed with with cystic fibrosis, spinal muscular atrophy, or Morquio Syndrome and the genetic testing of the embryo that results from in-vitro fertilization.

Collection Method: Claim data

	2019	2020	2021
Target	0.00	20.00	20.00
Baseline	0.00	0.00	0.00

By rule, performance notes are provided by the governmental entity that will supervise the new agency or administer the new program. Performance notes are not written by the Office of the Legislative Fiscal Analyst.